Towards Precision Therapy in Hepatocellular Carcinoma: A Clinical-Reasoning LLM for Risk Stratification and Treatment Guidance

Source

• Source name: arXiv
• Source kind: paper
• Authors / organization: Peng Cui, Jitao Wang, Siyan Xue, Yao Huang, Haoming Xia, Dong Li, Dengxiang Liu, Weilin Wang, Liping Liu, Leida Zhang, Yunfu Cui, Tao Peng, Daolin Ji, Haitao Zhao, Wei Zhang, Xiaojuan Wang, Weijie Ma, Zongren Ding, Jinlong Li, Yuan Ding, Jiajing Zhao, Zhiyu Chen, Chengkun Yang, Ziyue Huang, Jiaqi Liu, Fusheng Liu, Yang Zhou, Xiaojuan Wang, Zhongquan Sun, Shiyun Bao, Xiaojun Wang, Ming Yang, Guangxin Li, Bin Shu, Yong Liao, Hongxuan Li, Yao Tang, Shizhong Yang, Yongyi Zeng, Yufeng Yuan, Yinpeng Dong, Jihui Hao, Jun Zhu, Jiahong Dong
• Venue: arXiv: cs.AI
• Published: 2026-07-09
• Collected: 2026-07-10
• URL: http://arxiv.org/abs/2607.08602v1
• PDF: https://arxiv.org/pdf/2607.08602v1
• DOI: UNKNOWN

Plain-Language Brief

Researchers present HCC-STAR, a large language model that reads electronic medical records (EMRs) of patients with Hepatocellular Carcinoma (HCC), a common and deadly type of liver cancer. The model suggests treatments based on clinical guidelines, risk scores, and individualized survival estimates. It outperformed other models in a multi-center study in China and was found trustworthy by hepatobiliary specialists.

What the Document Says

• HCC-STAR is a large language model for Hepatocellular Carcinoma (HCC)
• It reads routine EMR narratives
• Outputs risk score-based staging, ranked guideline-consistent treatments with evidence-based rationales, and individualized survival estimates
• Developed using a clinician-validated, prompt-based augmentation workflow
• Curated about 30,000 HCC cases from SEER
• Performed state-of-the-art in treatment recommendation and risk stratification compared with clinical guidelines and competitive models like GPT-5 and Gemini-2.5 Pro
• Showed a median survival of 51 months under adherence to HCC-STAR recommendations, compared with 29 and 32 months under BCLC and CNLC
• In clinician-centric evaluations, hepatobiliary specialists found it trustworthy
• Surpassed resident and attending physicians in treatment accuracy and helped physicians make more accurate decisions faster when used as an assistant

Key Concepts Mentioned

• Hepatocellular Carcinoma (HCC)
• Electronic Medical Records (EMRs)
• large language model
• treatment recommendation
• risk stratification
• clinical guidelines
• SEER

Claims Made by the Document

• HCC-STAR outperformed other models in a multi-center study
• HCC-STAR's recommendations lead to a longer median survival than BCLC and CNLC

Evidence Used

• Multi-center cohort of 6,668 patients from 12 hospitals in China
• hypothetical overall-survival analysis

Methods / Approach

UNKNOWN

Limitations Stated by the Authors

UNKNOWN

Limitations Noted by the Agent

Agent interpretation — not from the source.

UNKNOWN

Open Questions

UNKNOWN

Notes for Future Q&A

May include interpretation. Labeled where it does.

UNKNOWN

Raw Abstract / Excerpt

Hepatocellular carcinoma (HCC) is a common malignancy and a leading cause of cancer-related mortality. Current guidelines and staging systems provide coarse categories, but often miss within-stage heterogeneity and the clinical context in electronic medical records (EMRs). We present HCC-STAR (Hepatocellular Carcinoma Staging, Treatment And pRognosis), a clinically aligned large language model that reads routine EMR narratives and jointly outputs risk score-based staging, ranked guideline-consistent treatments with evidence-based rationales, and individualized survival estimates. We curated about 30,000 HCC cases from SEER and expanded them into EMR-style narrative training data using a clinician-validated, prompt-based augmentation workflow. On this corpus, we developed a knowledge-aligned reasoning framework optimized with a step-verifiable composite reward, moving beyond text-level memorization of clinical guidelines. In a multi-center cohort of 6,668 patients from 12 hospitals in China, HCC-STAR achieved state-of-the-art performance in treatment recommendation and risk stratification compared with clinical guidelines and competitive models, including GPT-5 and Gemini-2.5 Pro. Hypothetical overall-survival analysis showed a median survival of 51 months under adherence to HCC-STAR recommendations, compared with 29 and 32 months under BCLC and CNLC. In clinician-centric evaluations, blinded hepatobiliary specialists rated HCC-STAR's reasoning and evidence-based justifications as trustworthy. The model surpassed resident and attending physicians in treatment accuracy and helped physicians make more accurate decisions faster when used as an assistant. These findings support HCC-STAR as a reliable and verifiable decision-support system for risk stratification and precision therapy in HCC.